Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
FatiAbGen Inc. logo — Best in class multi-modality antibodies for difficult target...

FatiAbGen Inc.

Best in class multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology

Founded 2020 Korea South Korea South 9 employees Seed Total: $3.00M Biopharma, Biotechnology +1

General Information

Company Name FatiAbGen Inc.
Founded Year 2020
Location Korea South Korea South
Employees 9
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Seed
Business Model B2B, B2B2B
Revenue Model Licensing, Project Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with FatiAbGen Inc.. To contact FatiAbGen Inc., visit fatiabgen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does FatiAbGen Inc. compare?

A PDF of FatiAbGen Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting FatiAbGen Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About FatiAbGen Inc.

FatiAbGen Inc., founded in 2020, is an innovative player in the Biopharma, Biotechnology, and Pharmaceutical industries. The company's slogan, "Best in class multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology," highlights its commitment to developing advanced therapies in areas of significant medical need.

As a pioneering Korean company, FatiAbGen's global integration is evident through its membership in Shonan iPark in Japan and the JLABS network in 2023. This strategic alignment with J&J’s portfolio underscores its reputation for innovation. The recent establishment of a subsidiary in Basel, Switzerland, in 2024, furthers its global business development pursuits, particularly for future out-licensing.

FatiAbGen secured a $2.00M Seed Round investment on 10 December 2023 from Asan Pharmaceutical, indicating robust investor confidence in its potential to address unmet needs in oncology and immunology.

Business keywords: multi-modality antibodies, oncology therapeutics, immunology therapeutics, antibody engineering, biotech collaboration, Shonan iPark, JLABS member, pre-clinical pipeline, antibody-drug conjugates, bi-specific antibodies, CAR-T technology, mesothelin targeting, solid tumor treatment, MSLN ADC, IgE therapies

Services & Products

Antibody Drug Development
Research in Oncology and Immunology
Joint R&D Collaborations

Target Customers

Healthcare Providers Biotech Firms Pharmaceutical Companies Academic and Research Institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $2.00M 1
Asan Pharmaceutical
10 Dec 2023
Seed Round $1.00M 1
UTC 2019 BioVentureFund
UTC 2019 BioVentureFund
01 Jan 2023

FatiAbGen Inc. Alternatives & Competitors

View All Alternatives
FatiAbGen Inc. vs
Iksuda Therapeutics
Iksuda Therapeutics United Kingdom

Creating class-leading ADCs with enhanced tumor specificity

Series A
43 employees
Biopharma, Biotechnology
Compare FatiAbGen Inc. vs Iksuda Therapeutics
FatiAbGen Inc. vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
FatiAbGen Inc. vs
ADC Therapeutics
ADC Therapeutics Switzerland

Innovating Science. Inspiring Hope.

252 employees
Biopharma, Biotechnology
Also compare with: FatiAbGen Inc. vs Alchemab Therapeutics Ltd Alchemab Therapeutics Ltd View all alternatives

FAQ About FatiAbGen Inc.

Best in class multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology
FatiAbGen Inc. was founded in 2020.
FatiAbGen Inc. is headquartered in Korea South.
FatiAbGen Inc. operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on multi-modality antibodies, oncology therapeutics, immunology therapeutics and antibody engineering. Its customers include Healthcare Providers, Biotech Firms and Pharmaceutical Companies.
FatiAbGen Inc. has a B2B and B2B2B business model. Its revenue comes from Licensing, Project Based and Service Fee.
FatiAbGen Inc. has approximately 9 employees.
FatiAbGen Inc. has completed 2 funding rounds, raising a total of $3.00M. The latest funding stage is Seed.
FatiAbGen Inc. offers: Antibody Drug Development, Research in Oncology and Immunology, Joint R&D Collaborations.
Top alternatives and competitors to FatiAbGen Inc. include Iksuda Therapeutics, Antharis Therapeutics, Inc., ADC Therapeutics, Pyxis Oncology, Alchemab Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FatiAbGen Inc. and Iksuda Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for FatiAbGen Inc., https://bouncewatch.com/company/fatiabgen-co-ltd, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout